A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Clinical trial NCT03953235 · COMPLETED

Trial details

NCT number: NCT03953235
Sponsor: Gritstone bio, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer Solid Tumor Shared Neoantigen-Positive Solid Tumors

Start date: 2019-07-18
Primary completion: 2023-03-10
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.